NSE: SUPRIYA | BSE: 543434

Expensive Star

Download real time

745.45 1.55 (0.21%)

125.89% Gain from 52W Low

249.0K NSE+BSE Volume

NSE 17 Apr, 2025 3:31 PM (IST)

5,999.6

Market Cap

Above industry Median

1.7

Beta 1Year

Very High Volatility

Supriya Lifescience Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SUPRIYA, BSE:543434 Supriya Lifescience Ltd.

Search Inside the pdf :

Supriya Lifescience Ltd.

28 Jan 2025

745.45

0.21%

Increased focus on niche therapies and regulated markets aid growth

Buy: Supriya Lifescience Ltd.

Target

KRChoksey

SUPRIYA revenue beat our estimates significantly due to strong growth in Analgesic segment and regulated markets. EBITDA and Adj. PAT exceeded our estimates significantly due to better-than-expected gross profit, and lower than expected operating expenses.

Number of FII/FPI investors increased from 69 to 85 in Dec 2024 qtr.

Supriya Lifescience Ltd.

29 Oct 2024

745.45

0.21%

Strong operational performance continue with multiple growth levers

Buy: Supriya Lifescience Ltd.

Target

KRChoksey

Supriya Lifescience revenue slightly missed (-1.2%) our estimate. However, EBITDA and PAT beat our estimates significantly due to lower-than-expected operating expenses, better product mix and better geographical mix.

Supriya Lifescience Ltd. has gained 102.82% in the last 1 Year

Supriya Lifescience Ltd.

14 Aug 2024

745.45

0.21%

Better product mix and geographical mix led to strong performance

Buy: Supriya Lifescience Ltd.

Target

KRChoksey

Supriya Lifescience’s revenue was in-line with our estimate. EBITDA beat our estimate due to lower-than-expected cost of goods sold and operating expenses.

Number of FII/FPI investors increased from 69 to 85 in Dec 2024 qtr.

Supriya Lifescience Ltd.

05 Jun 2024

745.45

0.21%

New product launches and new contracts to drive growth

Buy: Supriya Lifescience Ltd.

KRChoksey

Supriya Life science's revenue beat our estimate (+5.8%) due to growth in Vitamin and Anti-Histamine segment. The EBITDA beat our estimate (+22.4%) due to lower-than-expected employee expenses, and lower-than-expected other expenses.

Supriya Lifescience Ltd. has gained 30.19% in the last 6 Months

Supriya Lifescience Ltd.

14 Feb 2024

745.45

0.21%

Strong growth across the board on favorable geographical and product mix

Buy: Supriya Lifescience Ltd.

Recommendation Target

KRChoksey

For Q3FY24, SUPRIYA’s revenue grew by 33.2% YoY and stayed flat for QoQ at INR 1,401 Mn, while for 9MFY24, revenue grew by 29.3% YoY to INR 4,122 Mn. The Q3FY24 revenue growth was driven by analgesic/anti-pyretic/anaesthetic (49.0% of revenue in Q3FY24, +157.8% YoY), vitamin (14.0% of revenue, +14.0% YoY) and Anti-malarial (2.0% of revenue, +28.9% YoY), which was partially offset by anti-asthma (7.0% of revenue, -50.5% YoY), anti-Histamine (15.0% of revenue, -27.1% YoY) and anti-allergic (5.0% of revenue, -36.8% YoY). Geographically, Europe (42.0% contribution to Q3FY24 revenue vs 26.0% in Q3FY23) led the top-line momentum; Asia’s revenue contribution decreased to 42.0% from 50.0% in Q3FY23.

Supriya Lifescience .. has an average target of 740.00 from 1 broker.

Supriya Lifescience Ltd.

22 Dec 2023

745.45

0.21%

Pick of the Day (Short Term Delivery Call)

Accumulate: Supriya Lifescience Ltd.

SBI Securities

SLL has a niche product basket of 38 APIs with presence in therapeutic areas of Analgesics, Anti-histamine, vitamins, anti-asthmatics, anti-allergic and anti-malarial. The company has tied up with
Kalinga Institute of Technology for development of GelHeal and Quickblue Oral Kit.

Number of FII/FPI investors increased from 69 to 85 in Dec 2024 qtr.

Supriya Lifescience Ltd.

23 Nov 2023

745.45

0.21%

Solid revenue growth driven by volume increase

Accumulate: Supriya Lifescience Ltd.

Recommendation Target

KRChoksey

For Q2FY24, Supriya Lifescience's revenue grew 24.9% YoY and 6.1% QoQ to INR 1,401 Mn, while for H1FY24, revenue grew 27.4% YoY to 2,721 Mn. In terms of revenue break up, analgesic/anti-pyretic/anesthetic (56.0% share in Q2FY24) grew by 29.9% YoY, anti histamine (2.0% share in Q2FY24) grew by 21.8% YoY, vitamin (11.0% share in Q2FY24) grew by 26.3% YoY, anti-asthma (10.0% share in Q2FY24) grew by 26.2% YoY, anti-allergic (8.0% share in Q2FY24) grew by 31.9% YoY, anti-malarial (2.0% share in Q2FY24) grew by 3.8% YoY, and others (11.0% share in Q2FY24) grew by 3.4% YoY.

Number of FII/FPI investors increased from 69 to 85 in Dec 2024 qtr.

Supriya Lifescience Ltd.

31 May 2023

745.45

0.21%

Revenue recovered; challenges remain in china market

Buy: Supriya Lifescience Ltd.

Target

KRChoksey

Supriya Life Science reported a quarterly revenue growth of INR 1422.7 mn in Q4FY23, compared to INR 1051.0 mn in Q3FY23. The growth was primarily supported by strong traction in the US, Europe, and Latin America markets. Therapies such as Anti Anesthetic, Anti-Allergic, and Asthmatic played a key role in driving this growth.

Supriya Lifescience Ltd. has gained 24.77% in the last 1 Month

Supriya Lifescience Ltd.

20 Feb 2023

745.45

0.21%

Muted performance on account of multiple macro headwinds

Buy: Supriya Lifescience Ltd.

Target

KRChoksey

Supriya Life Science’s revenue has significantly declined in Q3FY23. The revenues stood at INR 1051.4mn against INR 1120.0mn in Q2FY23. The operating revenue for the 9 months was INR 3186.0mn Vs INR 3418.0mn in 9MFY22. During the quarter, the company's revenue was impacted by a slowdown in demand in a key market, namely China, as well as lower offtake for key products.

Supriya Lifescience Ltd. has gained 102.82% in the last 1 Year

Supriya Lifescience Ltd.

14 Nov 2022

745.45

0.21%

Demand visibility to continue

Buy: Supriya Lifescience Ltd.

Recommendation Target

KRChoksey

During Q2FY23, Supriya Lifescience Ltd (SLL) reported Revenue of INR 1,120 Mn (-25.33% YoY / +10.89% QoQ). Such growth was mainly driven by strong sales from Analgesic/Anestetic segment which contributed 56% to the topline against 36% in same period last year.

Supriya Lifescience Ltd. has gained 102.82% in the last 1 Year

VOTE: Is Supriya Lifescience Ltd. worth buying?

95 Votes:

Buy 85.26%

Sell 7.37%

Hold 7.37%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf